LBA4_PR - Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
| Autor: | Peters, S. 1, Ramalingam, S.S. 2, Paz-Ares, L. 3, Bernabe Caro, R. 4, Zurawski, B. 5, Kim, S.-W. 6, Alexandru, A. 7, Lupinacci, L. 8, de la Mora Jimenez, E. 9, Sakai, H. 10, Albert, I. 11, Vergnenegre, A. 12, Reck, M. 13, Borghaei, H. 14, Brahmer, J.R. 15, O’Byrne, K.J. 16, Geese, W.J. 17, Bhagavatheeswaran, P. 17, Nathan, F.E. 18, Hellmann, M.D. 19 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v913-v914 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|